PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Mosunetuzumab

Drugs in development · updated 30 October 2026

Mosunetuzumab: clinical trials and development status

Other names and codes: Lunsumio Velo

FDA verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 3 June 2022

As of 30 October 2026 Mosunetuzumab is in 44 active clinical trials (recruiting or ongoing, phases I–III) for 16 diseases. The most advanced phase is III.

44Active trials
IIIMost advanced phase
16Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Mosunetuzumab and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Follicular lymphomaIII15NCT04712097
Non-Hodgkin lymphomaIII5NCT05171647
Lymphoma, B-Cell, Marginal ZoneIII3NCT06006117
B-cell lymphomaII7NCT05410418
Diffuse large B-cell lymphomaII7NCT05633615
LymphomaII4NCT05410418
Chronic lymphocytic leukemiaI–II2NCT07052695
Hodgkin lymphomaII1NCT05615636
Interdigitating dendritic cell sarcomaII1NCT04889716
LeukemiaI–II1NCT07052695
Lupus nephritisII1NCT07598396
Lymphoid leukemiaII1NCT07566364
NeoplasmI–II1NCT06634589
Residual neoplasmII1NCT06828991
Systemic lupus erythematosusII1NCT07598396
Waldenstrom MacroglobulinemiaII1NCT07548450

Everything on Mosunetuzumab

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch